Please login to the form below
How can pharma help the NHS capitalise on its data?
Sue Thomas, Paul Midgley and Steve How, of Wilmington Healthcare, explain how pharma can work with the NHS to transform services
NHS
organisations cannot make significant improvements to their services without a detailed
knowledge and understanding of how they are currently performing, and where
problems and inefficiencies exist.
However,
although industries ranging from retail to insurance have been successfully
harnessing big data for years to improve products and services, the NHS has struggled
to capitalise on complex data.
For
example, critical data on admissions,
outpatient appointments and A&E attendances at NHS hospitals have been available via Public Health
Observatories and other sources for some time, and complemented by data on
specific diseases in recent years.
However,
commissioners have struggled to access it in order to plan and commission new
pathways, and have been further hampered by the fact that primary and secondary
care datasets have not been linked. Where they are taking advantage of data, it
is likely to be in priority disease areas only.
Consequently,
many NHS organisations do not know the full extent of how patients are
utilising their services and why. Similarly, they do not know where
improvements and cost-savings could be made by, for example, treating recurrent
infections in patients suffering from diseases such as multiple sclerosis at
primary care level to keep them out of hospital. These issues, combined with
time pressures on staff, mean that NHS organisations cannot benchmark their
services against other parts of the health service either.
How can pharma help?
With the NHS struggling to afford to capture,
procure and analyse its own data, there is a huge opportunity for pharma to
help shape the way that NHS services are delivered by gathering this data
themselves, analysing it and sharing the findings with CCGs, NHS trusts and new
emerging organisations.
At
Wilmington Healthcare, we draw on a variety of sources from NHS Digital, such
as Hospital Episode Statistics (HES), alongside interviews with stakeholders,
such as vanguards, CCGs and patients, to gather insight on trends, gaps or
inefficiencies in patient care in a variety of priority and non-priority
disease areas.
These
insights can be used to highlight the burden of disease; identify variations in
patient outcomes and provide evidence for change in therapeutic areas. They can
also help the NHS gain a clear understanding of the impact that pathways have
on patients’ experiences and outcomes, and highlight areas of best practice and
opportunities for improved efficiencies.
Thanks
to advanced data mining capabilities, information can be analysed at a granular
level to give a local and regional picture, as well as a national one. This
also means that the actual
causes for hospital admissions can be highlighted and followed over time, rather
than simply shown in ‘headline numbers’.
Where
there is a clear benefit to health and social care outcomes, such data can be
used by pharma to engage peer-to-peer
with trusts/CCGs and inform an initial ‘case for change’ for a particular
patient pathway, which can then lead to a detailed business case developed by a
multi-disciplinary group.
For example, one
pharma company has supported development of a disease insight report in
partnership with a charity to highlight a cross-sectional analysis of hospital
data. This revealed reasons for emergency hospital admissions – which can now
be tackled at a national level but the data also highlighted that the majority
of elective admissions (which were thought to be high) were in actual fact due
to an uptake of disease-modifying therapy.
Another pharma
company has supported development of an England-wide report to be used by an
All Party Parliamentary Group (APPG). These reports have been used effectively
to influence service design, health policy and improve patient outcomes.
As
new data sources become available following the amalgamation of health and
social care within STPs, Wilmington Healthcare will work with pharma and the
NHS to follow wider and more complex patient journeys that may, for example, go
from a GP to community services to hospital and then social care.
In
conclusion, there is a real opportunity for pharma to help shape NHS services
by gathering and analysing data around relevant disease areas and identifying
where it can help to improve patient outcomes and save money. Having access to
this kind of data can give pharma the edge by enabling it to approach a cash-strapped
NHS with solutions rather than problems.
Ends
Sue Thomas is CEO of the Commissioning Excellence Directorate; Paul
Midgley is Director of NHS insight; Steve How is Business Development Director,
all at Wilmington Healthcare. For information on Wilmington Healthcare, log on
to www.wilmingtonhealthcare.com
Contact
Website
Address:
Beechwood House
2-3 Commercial Way
Christy Close
Southfields
Basildon
SS15 6EF
United Kingdom
- UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW
- Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this latest quick-read briefing, Oli Hudson, Content Director at Wilmington Healthcare, lifts the veil on what place is, how it works and why it matters.
Wilmington Healthcare
- MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE
- With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is it responding to this challenge, and what can industry do to support it? Oli Hudson, Content Director at Wilmington Healthcare, explains what’s changing and how industry should respond.
Wilmington Healthcare
- ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS
- With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes and why they matter for pharma and med-tech companies.
Wilmington Healthcare
- HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW
- Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to the NHS and its prescribing behaviours during the peak of the pandemic. Oli Hudson summarises five of the key findings:
Wilmington Healthcare
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.
Wilmington Healthcare
- Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed
Wilmington Healthcare